356
Views
28
CrossRef citations to date
0
Altmetric
Research Article

To evaluate the change in release from solid dispersion using sodium lauryl sulfate and model drug sulfathiazole

, , &
Pages 1562-1572 | Received 09 Feb 2012, Accepted 26 Aug 2012, Published online: 03 Oct 2012

References

  • Aguiar AJ, Krc J, JrKinkel AW, Samyn JC. (1967). Effect of polymorphism on the absorption of Chloramphenicol palmitate. J Pharm Sci, 56: 84.
  • Serajuddin AT. (1999). Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci, 88:1058–1066.
  • Wing Lou C, Sidney R.. (1971). Pharmaceutical applications of solid dispersion system. J Pharm Sci, 60: 1281–1302.
  • Leuner C, Dressman J. (2000). Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 50:47–60.
  • Sekiguchi K, Obi N. (1961). Studies on absorption of eutectic mixtures I a comparison of the behavior of eutectic mixtures of sulfathiazole and that of ordinary sulfathiazole in man. Chem Pharm Bull, 9: 866.
  • Tachibana T, Nakamura A. (1965). A method for preparing an aqueous colloidal dispersion of organic materials by using water-soluble polymers: dispersion of beta-carotene by polyvinylpyrrolidone, Kolloid-Z. Polym, 203: 130–133.
  • Simonelli AP, Mehta SC, Higuchi WI. (1969). Dissolution rates of high energy polyvinylpyrrolidone (PVP)-sulfathiazole coprecipitates. J Pharm Sci, 58:538–549.
  • Matsumoto T, Zografi G. (1999). Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm Res, 16:1722–1728.
  • Van den Mooter G, Wuyts M, Blaton N, Busson R, Grobet P, Augustijns P et al. (2001). Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur J Pharm Sci, 12:261–269.
  • Ford JL. (1986). The current status of solid dispersions. Pharm Acta Helv, 61:69–88.
  • Simonelli AP, Mehta SC, Higuchi WI. Presented the Alpha Academy of pharmaceutical Sciences, Washington, and D.C. meeting. 1970.
  • Doherty C, York P. (1989). Accelerated stability of an X-ray amorphous furesemide-poly (vinylpyrrolidone) solid dispersion. Drug Dev Ind Pharm, 15: 1969–1987.
  • Najib NM, Suleiman M, Malakh A. (1986). Characteristics of the in vitro release of ibuprofen from polyvinylpyrrolidone solid dispersions. Int J Pharm, 32: 229–236.
  • Gibaldi M, Feldman S, Wynn R, Weiner ND. (1968). Dissolution rates in surfactant solutions under stirred and static conditions. J Pharm Sci, 57:787–791.
  • Sjokvist E, Nystrom C, Alden M. (1991). Physicochemical aspect of drug release XIII. The effect of sodium dodecyl sulphate additions on the structure and dissolution of a drug in solid dispersions. Int J Pharm, 69: 53–62.
  • Eva S, Christer N. (1992). Physicochemical aspects of drug release. XIV. The effects of some ionic and non ionic surfactants on properties of a sparingly soluble drug in solid dispersions. Int J Pharm, 79: 123–133.
  • Shah B, Kakumanu VK, Bansal AK. (2006). Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci, 95:1641–1665.
  • Baird JA, Taylor LS. (2012). Evaluation of amorphous solid dispersion properties using thermal analysis techniques. Adv Drug Deliv Rev, 64:396–421.
  • Dave HR, Patel DA, Edward D, Patel HH. (2012). To evaluate the effect of addition of an anionic surfactant on solid dispersion using model drug indomethacin. Drug Dev Ind Pharm, 38: 930–939.
  • Balani PN, Wong SY, Ng WK, Widjaja E, Tan RB, Chan SY. (2010). Influence of polymer content on stabilizing milled amorphous salbutamol sulphate. Int J Pharm, 391:125–136.
  • Marsac PJ, Rumondor AC, Nivens DE, Kestur US, Stanciu L, Taylor LS. (2010). Effect of temperature and moisture on the miscibility of amorphous dispersions of felodipine and poly(vinyl pyrrolidone). J Pharm Sci, 99:169–185.
  • Vasanthavada M, Tong WQ, Joshi Y, Kislalioglu MS. (2004). Phase behavior of amorphous molecular dispersions I: Determination of the degree and mechanism of solid solubility. Pharm Res, 21:1598–1606.
  • Khougaz K, Clas SD. (2000). Crystallization inhibition in solid dispersions of MK-0591 and poly(vinylpyrrolidone) polymers. J Pharm Sci, 89:1325–1334.
  • Hu Y, Erxleben A, Ryder AG, McArdle P. (2010). Quantitative analysis of sulfathiazole polymorphs in ternary mixtures by attenuated total reflectance infrared, near-infrared and Raman spectroscopy. J Pharm Biomed Anal, 53:412–420.
  • Silverstein M, Bassler C, Morril C. (1991). Spectrometric Identification of Organic Compounds. New York: Wiley; pp 91–131.
  • Doherty C, York P. (1987). Mechanisms of dissolution of furosemide/PVP solid dispersions. Int J Pharmaceut, 34: 197–205.
  • Clas S, Faizer R, Oconnor R, Vadas E. (1995). Quantification of crystallinity in blend of lyophilized and crystalline MK-0591 using X-ray-powder diffraction. Int J Pharm, 121: 73–79.
  • Rumondor AC, Taylor LS. (2010). Application of partial least-squares (PLS) modeling in quantifying drug crystallinity in amorphous solid dispersions. Int J Pharm, 398:155–160.
  • Chieng N, Rehder S, Saville D, Rades T, Aaltonen J. (2009). Quantitative solid-state analysis of three solid forms of ranitidine hydrochloride in ternary mixtures using Raman spectroscopy and X-ray powder diffraction. J Pharm Biomed Anal, 49:18–25.
  • Surana R, Suryanarayanan R. (2000). Quantification of crystallinity in substantially amorphous pharmaceutical and study of crystallization kinetics by X-ray powder diffractometry. Powder Diffr 15: 2–6.
  • Palanisamy M, Khanam J. (2011). Solid dispersion of prednisolone: solid state characterization and improvement of dissolution profile. Drug Dev Ind Pharm, 37:373–386.
  • He H, Yang R, Tang X. (2010). In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion. Drug Dev Ind Pharm, 36:681–687.
  • Taylor LS, Zografi G. (1997). Spectroscopic characterization of interactions between PVP and indomethacin in amorphous molecular dispersions. Pharm Res, 14:1691–1698.
  • Qi S, Weuts I, De Cort S, Stokbroekx S, Leemans R, Reading M et al. (2010). An investigation into the crystallisation behaviour of an amorphous cryomilled pharmaceutical material above and below the glass transition temperature. J Pharm Sci, 99:196–208.
  • Cheng Y, Ye X, Huang XD, Ma HR. (2006). Reentrant wetting transition on surfactant solution surfaces. J Chem Phys, 125:164709.
  • Bonnefond A, Paulis M, Leiza JR. (2011). Kinetics of the emulsion copolymerization of MMA/BA in the presence of sodium montmorillonite. Appl Clay Sci, 51: 110–116.
  • Srinarong P, Kouwen S, Visser MR, Hinrichs WL, Frijlink HW. (2010). Effect of drug-carrier interaction on the dissolution behavior of solid dispersion tablets. Pharm Dev Technol, 15:460–468.
  • Morris KR, Knipp GT, Serajuddin AT. (1992). Structural properties of polyethylene glycol-polysorbate 80 mixture, a solid dispersion vehicle. J Pharm Sci, 81:1185–1188.
  • Serajuddin AT, Sheen PC, Augustine MA. (1990). Improved dissolution of a poorly water-soluble drug from solid dispersions in polyethylene glycol: polysorbate 80 mixtures. J Pharm Sci, 79:463–464.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.